Outcomes and Guidelines for MRI in Patients With DCIS

Video

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.

Clinical Pearls I

- Outcome data should support the use of any expensive test

- Data does not exist to support the routine use of MRI in DCIS patients and invasive breast cancer patients

Clinical Pearls II

- It would be beneficial to have guidelines for the appropriate use of MRI

- Currently, the use of MRI is largely dependent on the surgeon and institution

Recent Videos
Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
Dietary Recommendations for Cancer Prevention and Supportive Care
Dietary Recommendations for Cancer Prevention and Supportive Care
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
Ropeginterferon Alfa Reduces JAK2 Allele Burden Over Long Term in PV
DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoid Tumors
DeFi Trial Update Shows Nirogacestat's Efficacy in Desmoid Tumors
Discussing Upcoming Data and Key Takeaways in Head and Neck Cancer
Discussing Upcoming Data and Key Takeaways in Head and Neck Cancer
Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Gadgeel on MARIPOSA Trial Updates in EGFR+ NSCLC
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer
Girard Shares Early COCOON Data of Amivantamab/Lazertinib in EGFR+ NSCLC
Girard Shares Early COCOON Data of Amivantamab/Lazertinib in EGFR+ NSCLC
Recent Failures Spur Innovation in Head and Neck Cancer Trials
Recent Failures Spur Innovation in Head and Neck Cancer Trials
Related Content
Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

Treating Metastatic Breast Cancer After Endocrine Therapy and T-DXd

Targeted Oncology Staff
March 31st 2025
Article

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

FDA Updates Decision on ProSense Cryoablation for Early-Stage Breast Cancer

FDA Updates Decision on ProSense Cryoablation for Early-Stage Breast Cancer

Jordyn Sava
March 20th 2025
Article

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.

Read More